What's Happening?
Leica Biosystems, a subsidiary of Danaher, has expanded its collaboration with AstraZeneca and Daiichi Sankyo to develop an immunohistochemistry (IHC) assay and image analysis algorithm for the TROP2 Normalized Membrane Ratio (NMR) biomarker in non-small
cell lung cancer. This collaboration builds on AstraZeneca's computational pathology algorithm and Leica's digital pathology solutions. The initiative aims to create an end-to-end solution for assessing novel biomarkers, advancing the application of digital and computational pathology tools. The collaboration reflects the industry's shift towards integrated digital ecosystems in pathology.
Why It's Important?
The expansion of Leica Biosystems' collaboration is crucial for advancing precision medicine, particularly in cancer diagnostics. By leveraging AI-assisted algorithms and digital pathology tools, the partnership aims to improve diagnostic precision and identify patients most likely to benefit from targeted therapies. This development could lead to more accurate and scalable diagnostic approaches, reducing the time and cost associated with developing life-changing therapies. The collaboration underscores the importance of integrating science, technology, and workflow to address complex challenges in biomarker research.
What's Next?
Leica Biosystems plans to leverage its digital pathology solutions to support the rapid development and global deployment of computational image analysis algorithms. The TROP2 NMR algorithm will be available through the Aperio AI Store, enabling users to evaluate and deploy tools within a unified digital pathology platform. The collaboration is expected to drive further advancements in computational pathology innovation, establishing an integrated pathway for diagnostic development from early assay feasibility to global deployment.
